(PUK) Prudential - Ratings and Ratios
Exchange: NYSE •
Country: Hong Kong •
Currency: USD •
Type: Common Stock •
ISIN: US74435K2042
Life, Health, Asset Management, Savings, Foreign Exchange
Dividends
| Dividend Yield | 1.53% |
| Yield on Cost 5y | 1.46% |
| Yield CAGR 5y | -9.44% |
| Payout Consistency | 89.8% |
| Payout Ratio | 37.2% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 28.4% |
| Value at Risk 5%th | 47.4% |
| Relative Tail Risk | 1.58% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.58 |
| Alpha | 88.79 |
| CAGR/Max DD | 0.13 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.439 |
| Beta | 0.858 |
| Beta Downside | 1.016 |
| Drawdowns 3y | |
|---|---|
| Max DD | 55.99% |
| Mean DD | 31.17% |
| Median DD | 34.18% |
Description: PUK Prudential December 03, 2025
Prudential plc (NYSE: PUK) operates through subsidiaries that deliver life and health insurance, as well as asset-management services, to individual customers across Asia and Africa. Its product suite includes savings and investment vehicles, wealth-protection solutions, health coverage, and foreign-exchange services. Founded in 1848, the firm is headquartered in Central, Hong Kong, and is classified under the GICS sub-industry “Life & Health Insurance.”
Key recent metrics show a 2023 net profit of US$ 2.1 billion, with a combined ratio of 94.5 %-indicating underwriting profitability despite a challenging low-interest-rate environment. The Asian market, especially China and India, remains a primary growth driver, supported by rising middle-class wealth and increasing demand for retirement and health products. Additionally, Prudential’s asset-management arm managed ≈ US$ 300 billion in assets under management (AUM) at year-end, benefitting from a shift toward fee-based investment solutions.
For a deeper, data-rich assessment of Prudential’s valuation and risk profile, you may find the analyst tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (3.53b TTM) > 0 and > 6% of Revenue (6% = 1.34b TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA 1.63pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 63.55% (prev 62.15%; Δ 1.40pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 3.62b > Net Income 3.53b (YES >=105%, WARN >=100%) |
| Net Debt (-310.0m) to EBITDA (13.43b) ratio: -0.02 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.25 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.31b) change vs 12m ago -4.49% (target <= -2.0% for YES) |
| Gross Margin 53.74% (prev 37.25%; Δ 16.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 12.22% (prev 5.24%; Δ 6.98pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 57.62 (EBITDA TTM 13.43b / Interest Expense TTM 241.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.25
| (A) 0.07 = (Total Current Assets 18.51b - Total Current Liabilities 4.35b) / Total Assets 199.12b |
| (B) 0.06 = Retained Earnings (Balance) 12.05b / Total Assets 199.12b |
| (C) 0.08 = EBIT TTM 13.89b / Avg Total Assets 182.29b |
| (D) 0.07 = Book Value of Equity 12.22b / Total Liabilities 179.68b |
| Total Rating: 1.25 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 77.33
| 1. Piotroski 5.50pt |
| 2. FCF Yield 8.21% |
| 3. FCF Margin 14.47% |
| 4. Debt/Equity 0.29 |
| 5. Debt/Ebitda -0.02 |
| 6. ROIC - WACC (= 41.84)% |
| 7. RoE 20.30% |
| 8. Rev. Trend 2.51% |
| 9. EPS Trend -4.59% |
What is the price of PUK shares?
As of December 23, 2025, the stock is trading at USD 31.37 with a total of 580,705 shares traded.
Over the past week, the price has changed by +4.74%, over one month by +13.70%, over three months by +12.72% and over the past year by +100.56%.
Over the past week, the price has changed by +4.74%, over one month by +13.70%, over three months by +12.72% and over the past year by +100.56%.
Is PUK a buy, sell or hold?
Prudential has received a consensus analysts rating of 4.67.
Therefore, it is recommended to buy PUK.
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PUK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 35.8 | 14.2% |
| Analysts Target Price | 35.8 | 14.2% |
| ValueRay Target Price | 36.1 | 15.1% |
PUK Fundamental Data Overview December 22, 2025
Market Cap USD = 39.04b (39.04b USD * 1.0 USD.USD)
P/E Trailing = 11.9535
P/E Forward = 13.8313
P/S = 2.9261
P/B = 2.1547
P/EG = 1.3565
Beta = 1.046
Revenue TTM = 22.28b USD
EBIT TTM = 13.89b USD
EBITDA TTM = 13.43b USD
Long Term Debt = 4.48b USD (from longTermDebt, last quarter)
Short Term Debt = 500.0m USD (from shortTermDebt, last quarter)
Debt = 5.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -310.0m USD (from netDebt column, last quarter)
Enterprise Value = 39.27b USD (39.04b + Debt 5.33b - CCE 5.10b)
Interest Coverage Ratio = 57.62 (Ebit TTM 13.89b / Interest Expense TTM 241.0m)
FCF Yield = 8.21% (FCF TTM 3.22b / Enterprise Value 39.27b)
FCF Margin = 14.47% (FCF TTM 3.22b / Revenue TTM 22.28b)
Net Margin = 15.86% (Net Income TTM 3.53b / Revenue TTM 22.28b)
Gross Margin = 53.74% ((Revenue TTM 22.28b - Cost of Revenue TTM 10.31b) / Revenue TTM)
Gross Margin QoQ = 63.95% (prev 9.09%)
Tobins Q-Ratio = 0.20 (Enterprise Value 39.27b / Total Assets 199.12b)
Interest Expense / Debt = 1.65% (Interest Expense 87.7m / Debt 5.33b)
Taxrate = 20.39% (351.0m / 1.72b)
NOPAT = 11.06b (EBIT 13.89b * (1 - 20.39%))
Current Ratio = 4.25 (Total Current Assets 18.51b / Total Current Liabilities 4.35b)
Debt / Equity = 0.29 (Debt 5.33b / totalStockholderEquity, last quarter 18.12b)
Debt / EBITDA = -0.02 (Net Debt -310.0m / EBITDA 13.43b)
Debt / FCF = -0.10 (Net Debt -310.0m / FCF TTM 3.22b)
Total Stockholder Equity = 17.40b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.77% (Net Income 3.53b / Total Assets 199.12b)
RoE = 20.30% (Net Income TTM 3.53b / Total Stockholder Equity 17.40b)
RoCE = 63.46% (EBIT 13.89b / Capital Employed (Equity 17.40b + L.T.Debt 4.48b))
RoIC = 50.08% (NOPAT 11.06b / Invested Capital 22.08b)
WACC = 8.24% (E(39.04b)/V(44.37b) * Re(9.18%) + D(5.33b)/V(44.37b) * Rd(1.65%) * (1-Tc(0.20)))
Discount Rate = 9.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.52%
[DCF Debug] Terminal Value 74.32% ; FCFE base≈3.22b ; Y1≈3.24b ; Y5≈3.47b
Fair Price DCF = 39.65 (DCF Value 50.19b / Shares Outstanding 1.27b; 5y FCF grow 0.0% → 3.0% )
EPS Correlation: -4.59 | EPS CAGR: -1.57% | SUE: 4.0 | # QB: 1
Revenue Correlation: 2.51 | Revenue CAGR: 22.49% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=2.37 | Chg30d=-0.007 | Revisions Net=-1 | Growth EPS=+16.7% | Growth Revenue=+13.8%
P/E Trailing = 11.9535
P/E Forward = 13.8313
P/S = 2.9261
P/B = 2.1547
P/EG = 1.3565
Beta = 1.046
Revenue TTM = 22.28b USD
EBIT TTM = 13.89b USD
EBITDA TTM = 13.43b USD
Long Term Debt = 4.48b USD (from longTermDebt, last quarter)
Short Term Debt = 500.0m USD (from shortTermDebt, last quarter)
Debt = 5.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -310.0m USD (from netDebt column, last quarter)
Enterprise Value = 39.27b USD (39.04b + Debt 5.33b - CCE 5.10b)
Interest Coverage Ratio = 57.62 (Ebit TTM 13.89b / Interest Expense TTM 241.0m)
FCF Yield = 8.21% (FCF TTM 3.22b / Enterprise Value 39.27b)
FCF Margin = 14.47% (FCF TTM 3.22b / Revenue TTM 22.28b)
Net Margin = 15.86% (Net Income TTM 3.53b / Revenue TTM 22.28b)
Gross Margin = 53.74% ((Revenue TTM 22.28b - Cost of Revenue TTM 10.31b) / Revenue TTM)
Gross Margin QoQ = 63.95% (prev 9.09%)
Tobins Q-Ratio = 0.20 (Enterprise Value 39.27b / Total Assets 199.12b)
Interest Expense / Debt = 1.65% (Interest Expense 87.7m / Debt 5.33b)
Taxrate = 20.39% (351.0m / 1.72b)
NOPAT = 11.06b (EBIT 13.89b * (1 - 20.39%))
Current Ratio = 4.25 (Total Current Assets 18.51b / Total Current Liabilities 4.35b)
Debt / Equity = 0.29 (Debt 5.33b / totalStockholderEquity, last quarter 18.12b)
Debt / EBITDA = -0.02 (Net Debt -310.0m / EBITDA 13.43b)
Debt / FCF = -0.10 (Net Debt -310.0m / FCF TTM 3.22b)
Total Stockholder Equity = 17.40b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.77% (Net Income 3.53b / Total Assets 199.12b)
RoE = 20.30% (Net Income TTM 3.53b / Total Stockholder Equity 17.40b)
RoCE = 63.46% (EBIT 13.89b / Capital Employed (Equity 17.40b + L.T.Debt 4.48b))
RoIC = 50.08% (NOPAT 11.06b / Invested Capital 22.08b)
WACC = 8.24% (E(39.04b)/V(44.37b) * Re(9.18%) + D(5.33b)/V(44.37b) * Rd(1.65%) * (1-Tc(0.20)))
Discount Rate = 9.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.52%
[DCF Debug] Terminal Value 74.32% ; FCFE base≈3.22b ; Y1≈3.24b ; Y5≈3.47b
Fair Price DCF = 39.65 (DCF Value 50.19b / Shares Outstanding 1.27b; 5y FCF grow 0.0% → 3.0% )
EPS Correlation: -4.59 | EPS CAGR: -1.57% | SUE: 4.0 | # QB: 1
Revenue Correlation: 2.51 | Revenue CAGR: 22.49% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=2.37 | Chg30d=-0.007 | Revisions Net=-1 | Growth EPS=+16.7% | Growth Revenue=+13.8%
Additional Sources for PUK Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle